Abstract
The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the antiviral effect of CT-P59 on Gamma, Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal studies. CT-P59 showed neutralization against Gamma, Delta, Epsilon, and Kappa variants in cells, with reduced susceptibility. The mouse challenge experiments with Gamma and Delta variants substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against Gamma and Delta variants infection, hinting that CT-P59 has therapeutic potential for patients infected with Gamma, Delta and its associated variants.
Keywords: CT-P59; Delta; Gamma; Regdanvimab; SARS-CoV-2 variant; Therapeutic antibody.
【저자키워드】 SARS-CoV-2 variant, Delta, Gamma, regdanvimab, CT-P59, Therapeutic antibody., 【초록키워드】 SARS-CoV-2, antibody, neutralization, susceptibility, variant, SARS-CoV-2 variant, Infection, Symptom, delta variant, virus, variants, Antiviral effect, infections, L452R, cells, Epsilon, Patient, Beta, respiratory tract, experiment, respiratory, in vivo, regdanvimab, therapeutic potential, beta variants, abrogation, effective, Cell, carried, reported, reduced, question, cause, experiments, remains uncertain, 【제목키워드】 Efficacy, in vitro, in vivo, variants of SARS-CoV-2,